PA
ATRA icon

Pinnacle Associates’s Atara Biotherapeutics ATRA Stock Holding History

Pinnacle Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-510
Closed -$8.84K – 815
2024
Q1 		$8.84K Sell
510
-42
-8% -$746 ﹤0.01% 832
2023
Q4 		$7.07K Sell
552
-14,863
-96% -$347K ﹤0.01% 816
2023
Q3 		$570K Sell
15,415
-409
-3% -$18.2K 0.01% 542
2023
Q2 		$637K Sell
15,824
-149
-0.9% -$8.43K 0.01% 539
2023
Q1 		$1.16M Buy
15,973
+245
+2% +$23.8K 0.02% 388
2022
Q4 		$1.29M Sell
15,728
-209
-1% -$21.8K 0.03% 363
2022
Q3 		$1.51M Sell
15,937
-1,211
-7% -$136K 0.03% 327
2022
Q2 		$3.34M Sell
17,148
-43
-0.3% -$7.02K 0.07% 244
2022
Q1 		$3.99M Sell
17,191
-797
-4% -$254K 0.07% 251
2021
Q4 		$7.09M Sell
17,988
-85
-0.5% -$35.8K 0.12% 185
2021
Q3 		$8.09M Sell
18,073
-605
-3% -$217K 0.15% 163
2021
Q2 		$7.26M Buy
18,678
+274
+1% +$97.7K 0.13% 169
2021
Q1 		$6.61M Sell
18,404
-1,798
-9% -$795K 0.13% 177
2020
Q4 		$9.91M Sell
20,202
-1,421
-7% -$656K 0.2% 129
2020
Q3 		$7.01M Sell
21,623
-454
-2% -$155K 0.17% 147
2020
Q2 		$8.04M Buy
22,077
+5,038
+30% +$1.27M 0.2% 129
2020
Q1 		$3.63M Buy
17,039
+4,078
+31% +$1.29M 0.11% 193
2019
Q4 		$5.34M Buy
+12,961
New +$4.47M 0.12% 198

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pinnacle Associates's ATRA Position: Q2 2024 in Review

Pinnacle Associates sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 510 shares — an estimated $8.84K sold.

Pinnacle Associates first reported a position in ATRA in Q4 2019 and held it in 18 quarters. The position peaked at $9.91M in Q4 2020. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Pinnacle Associates reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Pinnacle Associates sold 510 Atara Biotherapeutics shares in Q2 2024, an estimated $8.84K.
  • Pinnacle Associates first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 18 quarters.
  • Pinnacle Associates's Atara Biotherapeutics position peaked at $9.91M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Pinnacle Associates's 13F filing for Q2 2024, filed 30 Jul 2024.